Range Low Price High Price Comment
30 days $3.25 $5.08 Monday, 29th Apr 2024 AVXL stock ended at $3.65. This is 6.10% more than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 9.82% from a day low at $3.41 to a day high of $3.75.
90 days $3.25 $6.67
52 weeks $3.25 $10.31

Historical Anavex Life Sciences Corp. prices

Date Open High Low Close Volume
Feb 01, 2016 $3.60 $3.95 $3.51 $3.89 551 800
Jan 29, 2016 $3.42 $3.62 $3.37 $3.59 555 300
Jan 28, 2016 $3.65 $3.74 $3.41 $3.43 427 600
Jan 27, 2016 $3.76 $3.83 $3.58 $3.60 730 400
Jan 26, 2016 $4.06 $4.18 $3.78 $3.81 945 700
Jan 25, 2016 $3.70 $4.18 $3.50 $4.12 1 034 100
Jan 22, 2016 $3.65 $3.78 $3.53 $3.66 457 200
Jan 21, 2016 $3.55 $3.88 $3.52 $3.61 727 500
Jan 20, 2016 $3.55 $3.60 $3.29 $3.58 1 372 400
Jan 19, 2016 $4.02 $4.07 $3.65 $3.72 1 168 800
Jan 15, 2016 $3.76 $4.18 $3.76 $4.01 1 063 000
Jan 14, 2016 $3.77 $4.29 $3.30 $4.05 2 056 300
Jan 13, 2016 $4.05 $4.05 $3.50 $3.67 2 196 300
Jan 12, 2016 $5.03 $5.09 $4.06 $4.10 2 671 100
Jan 11, 2016 $5.68 $5.80 $4.82 $5.16 5 171 500
Jan 08, 2016 $4.70 $4.88 $3.77 $4.60 3 325 000
Jan 07, 2016 $4.98 $5.11 $4.47 $4.53 1 951 500
Jan 06, 2016 $6.05 $6.05 $4.95 $5.11 2 632 800
Jan 05, 2016 $6.12 $6.33 $6.00 $6.12 1 436 100
Click to get the best stock tips daily for free!

About Anavex Life Sciences Corp.

Anavex Life Sciences . Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinica... AVXL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT